Key takeaways
- Testosterone pellets usually last three to six months; in our practice, men typically go five to six months between insertions and women three to five.
- Levels peak about a month after insertion. In studies of men, sexual interest changed around three weeks; body composition took three to four months.
- Tenderness or bruising for a few days is common. Infection or a pellet working its way out is uncommon, and most reported cases occur in the first month.
- Your schedule should follow your labs and symptoms, not the calendar alone. Monitoring includes testosterone, hematocrit, blood pressure and, for men, PSA.
- Testopel is FDA-approved for men with specific causes of low testosterone. No pellet is FDA-approved for women, and compounded pellets are not FDA-approved products.
Pellets are one of the most convenient ways to take testosterone: a few minutes in the office, then nothing to take or apply for months. The most common question is simple: how long will this last, and what happens before the next one? Here is what the FDA label, the major guidelines, and the research say.
How long do testosterone pellets last?
For most people, somewhere between three and six months. Where you land depends on the dose, the type of pellet, and your own body.
For men, the label for Testopel, an FDA-approved testosterone pellet, says its effect usually lasts three to four months, sometimes six. The Endocrine Society says levels peak about a month after insertion. They then stay in the normal range for three to six months, depending on the formulation.
In our practice, men's testosterone pellets typically last five to six months. Women's testosterone and estrogen pellets typically last three to five months. These are typical ranges, not promises; your labs and symptoms set your own schedule.
Pellets also don't stop working on a single day. The Testopel label estimates that a third of the dose is absorbed in the first month. A quarter follows in the second month and a sixth in the third. Levels drift down gradually rather than dropping off all at once.
What the first two weeks feel like
The insertion itself is quick. We numb a small area, usually the upper buttock or hip, make a tiny incision, and place the rice-sized pellets just under the skin. Most patients describe pressure rather than pain.
For the next few days, expect some tenderness and possibly a bruise. Keep the dressing clean and dry. Skip baths, pools, and hot tubs, and avoid strenuous lower-body exercise for a few days while the incision heals.
Don't judge the pellet by the first few days. Levels rise over the first weeks and peak around one month. In a review of testosterone studies in men, changes in sexual interest appeared after about three weeks and leveled off by six. Effects on quality of life showed up within three to four weeks, and effects on mood within three to six. Changes in body fat and muscle took twelve to sixteen weeks. Individual experience varies.
For women, a 2019 global consensus statement recommends stopping testosterone if it hasn't helped by six months, so give it time before judging.
Call us if the site gets more red, warm, swollen, or painful instead of less, if it drains, or if you run a fever. Also call if a pellet begins to work its way out. These problems are uncommon, and most reported cases happen within the first month.
When we recheck your levels
Guidelines give a framework, and we fit it to you. For men using Testopel, the American Urological Association lists testosterone checks at two weeks and twelve weeks after each insertion. The Endocrine Society recommends checking testosterone and hematocrit three to six months after starting, at twelve months, and then yearly.
For women using testosterone, the 2019 consensus statement recommends a level before starting and a repeat three to six weeks in. After that, it recommends a review every six months for benefit and for signs of too much testosterone. Monitoring usually covers:
- Testosterone and, for many patients, estradiol. For men, the AUA recommends aiming for the middle of the normal range, roughly 450 to 600 ng/dL.
- Hematocrit, the share of your blood made up of red cells, which testosterone can push too high.
- Blood pressure. In 2025 the FDA extended a warning to all testosterone products that testosterone can raise blood pressure. The same update reported that the large TRAVERSE trial found no increase in the risk of adverse cardiovascular outcomes in men treated for low testosterone.
- PSA for men over 40: before starting, again within the first year, then on a standard prostate-screening schedule.
We recheck labs to plan each next insertion. The numbers are only half the story, though. How you feel, how you sleep, and your energy count just as much.
Why your timing may differ from someone else's
Pellet schedules vary from person to person for a few reasons.
- Dose. Pellet doses vary widely between products and patients, and the size of the dose affects how long it lasts.
- Formulation. The Endocrine Society notes that how long pellets keep levels in the normal range depends on the formulation.
- Your own body. People absorb and use testosterone differently. That is why guidelines call for a follow-up level after treatment starts instead of assuming a dose works the same for everyone.
- Your symptoms. When a pellet wears off, the symptoms that brought you in tend to come back. Tell us when you notice them. That timing, together with your labs, sets your next insertion.
One practical point: a pellet can't be adjusted once it's placed. The Testopel label calls pellets much less flexible for dose changes than pills or injections. By its estimate, about a quarter of the dose is still unabsorbed after three months. New pellets placed too early can stack on top of what's left, so we don't re-dose by the calendar alone.
Are pellets the right choice for you?
Pellets are one option among several, and they aren't right for everyone. A few facts are worth weighing.
- FDA status for men. Testopel is FDA-approved for men whose low testosterone has specific testicular, pituitary, or hypothalamic causes. Its label notes that safety and effectiveness in age-related low testosterone have not been established. Compounded testosterone pellets, like all compounded medications, are not FDA-approved. It's reasonable to ask which product you are receiving.
- FDA status for women. No pellet is FDA-approved for women; the testosterone and estradiol pellets used for women are compounded. A 2019 global consensus statement on testosterone for women recommends against preparations that produce above-normal levels, naming pellets and injections. It adds that compounded testosterone can't be recommended because evidence on safety and efficacy is lacking. The only use the statement considers evidence-based is distressing low sexual desire after menopause.
- Fertility and pregnancy. Testosterone can lower sperm production, and the AUA advises against it for men who are trying to conceive. If fertility matters to you, we'll discuss other approaches. Testosterone is contraindicated in pregnancy because it can harm a developing baby.
- Other conditions. Testosterone is not used in men with breast cancer or known or suspected prostate cancer.
We take these cautions seriously. It's why we start with labs and, in many cases, another delivery method first, so we know how you respond before a pellet is placed. Injections, creams, troches, and pills are easier to adjust and don't require a procedure. If your labs and symptoms point to a need for hormone therapy, the delivery method is your choice when it is clinically appropriate.
The bottom line
Testosterone pellets usually last three to six months. The first weeks bring a sore spot and a gradual rise in levels, not an overnight change. Your labs and symptoms, not the calendar alone, should set your schedule. If you're considering pellets or wondering whether your current schedule is right, book a complimentary consultation. We'll review your history and labs and help you choose the approach that fits.
Sources
- TESTOPEL (testosterone pellets) prescribing information, Endo USA, revised July 2025 (DailyMed, U.S. National Library of Medicine)
- U.S. FDA: FDA issues class-wide labeling changes for testosterone products, February 28, 2025
- Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018;103:1715-1744.
- Mulhall JP, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018; validity confirmed 2024). American Urological Association.
- Saad F, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675-685.
- Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab 2019;104:4660-4666.
- U.S. FDA: Compounding and the FDA: Questions and Answers
Website content is for general education and does not replace individualized medical advice, diagnosis, or treatment. Individual results vary. This article is general education from a Florida physician and does not create a doctor–patient relationship; talk with your own clinician about your situation.
